Arcellx posts Q4 net income of $20.5M, cash $729.2M, expands Kite partnership

Arcellx, Inc.

2023-FY EPS reported -$1.47 revenue$110,319,000

Q4 2023 net income $20.5M vs net loss $39.0M in Q4 2022; full-year net loss narrowed to $70.7M from $188.7M.
Cash, cash equivalents and marketable securities $729.2M; cash runway extended into 2027.
Collaboration revenue from Kite partnership: $63.1M in Q4 and $110.3M full year, both vs zero.
Kite partnership expanded with $200M equity investment at $61.68/share and $85M upfront cash, plus co-development of anito-cel for lymphomas.
Phase 1 anito-cel data: 100% ORR, 76% CR/sCR (29/38 patients), no delayed neurotoxicity, median DOR/PFS/OS not reached.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcellx, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $63.1 million, net income $20.5 million.

Period: the fourth quarter and year ended December 31, 2023
Revenue: $63.1 million
Net income: $20.5 million
Result: reported results

Exact text from the filing

million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027. Collaboration revenue: Collaboration revenue was $63.1 million and zero for the quarters ended December 31, 2023 and 2022, respectively. Collaboration revenue was $110.3 million and zero for the twelve months ended December 31, 2023 and

View on SEC.gov

Browse all earnings releases →

Arcellx, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-022046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.